METHIONINE C-11 is a synthetic amino acid radiolabeled with carbon-11. Acting as a methyl donor, methionine C 11 is incorporated into macromolecules, where it serves as a positron emission tomography (PET) imaging agent for detecting tumors with high rates of protein synthesis. METHIONINE C-11 is produced without any significant radiochemical impurities.

Cocaethylene is the ethyl ester of benzoylecgonine. Cocaethylene is formed in the liver after concurrent use of cocaine and alcohol. Cocaethylene works by blocking the dopamine transporter on dopaminergic presynaptic nerve terminals in the brain. It increases dopamine synaptic content, provoking enhanced postsynaptic receptor stimulation, resulting in euphoria, reinforcement, and self-administration. Compared to cocaine, which is a methyl ether of benzoylecgonine, cocaethylene has three to five times larger half-life in plasma. Cocaethylene is associated with seizures, liver damage and compromised the functioning of the immune system. It carries an 18-25 fold increase in risk for immediate death compared to cocaine alone.

Ascorbyl gamolenate, an aldehyde reductase inhibitor, participated in phase-I clinical trials for Diabetic neuropathies in the United Kingdom but these studies were discontinued.

Rebimastat (BMS-275291) is a broad-spectrum matrix metalloproteinase (MMP) inhibitor free from toxicity-related inhibition of sheddases (cleaving membrane proteins at the cell surface). This MMP2 and MMP9 inhibitor may stop the growth of cancers by stopping blood flow to the tumor (stopping them from dividing). It might also block the enzymes necessary for growth of the tumor cell. Multiple phase II trials and a phase III clinical trial have been completed, testing the efficacy and safety of the compound in prostate cancer, HIV-related Kaposi’s Sarcoma, non-small cell lung cancer (phase II and III) and breast cancer.

Dexivacaine is a local anesthetic drug that has minimal and non-significant side effects.

(S)-baclofen (or L-baclofen) is an enantiomer of baclofen, a direct GABA-B receptor mimetic. L-baclofen represents a significant improvement over racemic baclofen in the treatment of trigeminal neuralgia.

Thymocartin (also known as T4 and RGH-0206) is a protected synthetic tetrapeptide patented by Hungarian multinational pharmaceutical and biotechnology company Gedeon Richter Plc. (Richter, Gedeon, Vegyeszeti Gyar Rt) as an immunomodulating agent. In preclinical models, Thymocartin shows to exert similar immunomodulatory activities to thymopoietin affecting both humoral and cellular responses. In skin graft mouse model Thymocartin increases the number of splenic T cells and restored the rejection capacity of thymectomized C57Bl mice. In chronic 28-days i.v. toxicity studies in dogs no adverse reaction has been found. The low toxicity of Thymocartin is probably attributable to their short half-life as the half-life of the Thymocartin is less than 3 min in humans.

Nonathymulin (Thymulin, FTS) is well defined nonapeptide hormone produced by thymic epithelial cells. Its biological activity and antigenicity depend upon the presence of the metal zinc in the molecule. Thymulin consists of a biologically inactive nonapeptide component termed FTS (anacronym for serum thymus factor in French) coupled in an equimolecular ratio to the ion zinc, which confers biological activity to the molecule. This pharmacologically active metallopeptide induces the differentiation of T-cells and enhances several functions of the various T-cell subsets in normal or partially thymus-deficient recipients. The peptide is a natural hormone, available in synthetic form. Thymulin has a selective immunomodulatory effect, enhancing anti-inflammatory and inhibiting pro-inflammatory cytokines. It suppresses p38 (implicated in glucocorticoid-resistance) and inhibits NF-kappaB activation, which has an important pathogenic role in several lung diseases. The broad spectrum of anti-inflammatory effects of this peptide in several animal models of lung disease makes thymulin a good candidate for future clinical trials. Thymulin was being investigated by Santen Pharmaceutical in Japan. Its development for the treatment of ischaemic heart disorders and rheumatoid arthritis in Japan was discontinued. Thymulin is probably the best characterized of all putative thymic hormones and seems to playa physiological role in thymus–pituitary communication, particularly during perinatal life. Interest in the therapeutic use of thymulin flourished during the 1970s and 1980s when efforts were almost exclusively focused on using thymulin for the treatment of autoimmune and other immunopathologies as well as cancer. Subsequent studies established that thymulin is active on the hypophysis and the brain. This awareness and the availability of a synthetic gene for metFTS have opened new avenues for the exploration and eventual exploitation of the therapeutic potential of this metallopeptide.